SLC2A2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5341068	0.52	14/20
SCHEMBL1691330	0.48	14/20
SCHEMBL1691422	0.48	13/20
SCHEMBL838296	0.66	11/20
SCHEMBL1691850	0.46	11/20
SCHEMBL838951	0.65	10/20
SCHEMBL6205196	0.65	10/20
SCHEMBL5336388	0.47	10/20
SCHEMBL8344599	0.58	9/20
SCHEMBL7658416	0.68	8/20
SCHEMBL798557	0.37	8/20
SCHEMBL686720	0.35	8/20
SCHEMBL2628836	0.77	7/20
SCHEMBL6706131	0.65	7/20
SCHEMBL6224888	0.61	7/20
Hydrochloric Acid (SCHEMBL6205326)	0.60	7/20
SCHEMBL1791137	0.58	7/20
SCHEMBL838206	0.56	7/20
SCHEMBL1691228	0.53	7/20
SCHEMBL798149	0.36	7/20

Clinical trials — most relevant to SLC2A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.	PHASE4	COMPLETED
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration	PHASE4	COMPLETED
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes	PHASE4	COMPLETED
Effect of Anti-diabetic Drugs on Glycemic Variability	PHASE4	COMPLETED
Dapagliflozin Effect on Erythropoiesis and Physical Fitness	PHASE4	WITHDRAWN
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients	PHASE4	COMPLETED
Reformulated F75 Milk to Treat Severe Acute Malnutrition	PHASE2/PHASE3	COMPLETED
Empagliflozin in Hypertrophic Cardiomyopathy	PHASE3	ACTIVE_NOT_RECRUITING
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin	PHASE2	NOT_YET_RECRUITING
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes	PHASE2	COMPLETED
PK and PD of YG1699 in CKD Patients With Diabetes	PHASE1	NOT_YET_RECRUITING
Multi-Tracer PET Assessment of Primary Brain Tumors	PHASE1	COMPLETED
Sodium Lactate Infusion in GLUT1DS Patients	EARLY_PHASE1	COMPLETED
Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography	nan	NOT_YET_RECRUITING
A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis	nan	RECRUITING
Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome	nan	SUSPENDED
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients	nan	COMPLETED
Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure	nan	COMPLETED
Clinical Utility of Breath Tests in GI	nan	COMPLETED
SLC2A1 Variants and Diabetic Nephropathy	nan	COMPLETED
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer	nan	UNKNOWN
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.	nan	RECRUITING
Hepatic Substrate Flux Rates in Type 2 Diabetes	nan	ACTIVE_NOT_RECRUITING
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction	nan	COMPLETED
The Effect of Artificial Sweeteners on Blood Glucose Response	nan	WITHDRAWN
Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment	nan	COMPLETED
Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore	nan	COMPLETED
Harmonic Ratio in Patients With GLUT1 Deficiency Syndrome	nan	ACTIVE_NOT_RECRUITING
Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus	nan	COMPLETED
Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC2A2 binder may also engage these)

Protein	Name	Similarity
O62786	—	1.000	O62786 →
P12336	—	1.000	P12336 →
P14246	—	0.998	P14246 →
Q9XSC2	—	0.998	Q9XSC2 →
P47842	—	0.994	P47842 →
Q5R608	—	0.993	Q5R608 →
SLC2A3	Solute carrier family 2, facilitated glucose transporter member 3	0.993	landscape →
P47843	—	0.993	P47843 →
Q90592	—	0.992	Q90592 →
O62787	—	0.992	O62787 →
Q8TDB8	—	0.992	Q8TDB8 →
P46896	—	0.990	P46896 →
P58351	—	0.990	P58351 →
O44827	—	0.989	O44827 →
P79365	—	0.989	P79365 →
P58352	—	0.989	P58352 →
A9ZSY3	—	0.988	A9ZSY3 →
P28568	—	0.987	P28568 →
Q07647	—	0.986	Q07647 →
P13355	—	0.985	P13355 →
P17809	—	0.985	P17809 →
P43427	—	0.985	P43427 →
SLC2A1	Solute carrier family 2, facilitated glucose transporter member 1	0.985	landscape →
P11167	—	0.983	P11167 →
P27674	—	0.983	P27674 →
A9ZSY2	—	0.983	A9ZSY2 →
A5LGM7	—	0.982	A5LGM7 →
Q9C757	—	0.981	Q9C757 →
P20303	—	0.981	P20303 →
Q9VCA2	—	0.981	Q9VCA2 →